FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W52984345> ?p ?o ?g. }

• W52984345 endingPage "200" @default.
• W52984345 startingPage "187" @default.
• W52984345 abstract "Background : It has been widely accepted that the epitope (s) and/or functional characteristics of thyrotropin receptor antibodies (TSHRAb) from Graves’ patients are heterogenous among patients. However, the clinical significance of such heterogeneity has not been systematically evaluated yet. We were to elucidate and find the clinical significance of heterogeneity for TSH receptor antibodies in Graves’ disease. Methods : We measured stimulating TSHRAb (TSAb) activities using CHO-hTSHR cells, FRTL-5 cells and chimeric receptor expressing cells (Mcl+2 and Mc2), specific blocking TSHRAb (TSBAb) activities using Mc2 cells and TBII activities using porcine thyroid membrane in 136 patients with untreated hyperthyroid Graves’ disease. Results : Based on various TSHRAb activities from each patient, the patients could be categorized into 7 subgroups by cluster analysis: 1) Group 1 (n=41) was characterized by moderate TSAb activities both in CHO-hTSHR cells and in FRTL-5 cells, typical TSAb epitope, rare blocking antibodies and high TBII activities. 2) Group 2 (n=16) was characterized by the presence of blocking TSHRAb in most patients, albeit the other characteristics were the same as those in Group 1. 3) Group 3 (n=19) patients had low TSAb activities both in CHO-hTSHR cells and in FRTL-5 cells, seldom had blocking TSHRAb, but they had high TBII activities. 4) Group 4 (n = 30) could be categorized as ‘mild disease’ group, as they had low activities in all kinds of TSHRAb assay and had low antimicrosomal antibody activities. 5) Group 5 (n=14) was characterized by moderate TSAb activities with atypical epitope (s), rare blocking TSHRAb and moderate TBII activities. 6) Group 6 (n=10) patients had very high TSAb activities with typical epitopes, seldom blocking TSHRAb and low TBII activities. 7) Group 7 (n = 6) was characterized by very high TSAb activities with atypical epitopes and high TBII activities. Pretreatment serum thyroid hormone level was low only in group 4 patients compared to the other 6 groups (p<0.05). The size of goiter was significantly larger in those in group 1 and group 3 (p<0.05) compared to the other 5 groups. The prevalence of clinically significant ophthalmopathy was higher in group 2 patients than the other 6 groups (50% vs. 27.5%, p=0.06). Among 6 kinds of TSHRAb activities, only the blocking TSHRAb activity was significantly associated with the presence of ophthalmopathy in multivariate analysis. Conclusion : These results suggest that the differences in epitopes for TSAb or the presence of blocking TSHRAb is not a major factor in determining the degree of thyrotoxicosis in Graves’ disease. Although the pathogenic mechanism is not clear yet, we suggest that patients with ophthalmopathy have different TSHRAb repertoire from those without ophthalmopathy in Graves’ disease." @default.
• W52984345 created "2016-06-24" @default.
• W52984345 creator A5004961134 @default.
• W52984345 creator A5023837417 @default.
• W52984345 creator A5039000978 @default.
• W52984345 creator A5048656815 @default.
• W52984345 creator A5061142393 @default.
• W52984345 creator A5065930316 @default.
• W52984345 date "2001-09-30" @default.
• W52984345 modified "2023-09-30" @default.
• W52984345 title "Clinical Significance of Classification of Graves` Disease According to the Characteristics of TSH receptor Antibodies" @default.
• W52984345 cites W1424218273 @default.
• W52984345 cites W1965113827 @default.
• W52984345 cites W1966102618 @default.
• W52984345 cites W1968805927 @default.
• W52984345 cites W1976294116 @default.
• W52984345 cites W1979167514 @default.
• W52984345 cites W1984507564 @default.
• W52984345 cites W1989298729 @default.
• W52984345 cites W2001676232 @default.
• W52984345 cites W2013008197 @default.
• W52984345 cites W2017353779 @default.
• W52984345 cites W2017686558 @default.
• W52984345 cites W2022468439 @default.
• W52984345 cites W2022583652 @default.
• W52984345 cites W2026013057 @default.
• W52984345 cites W2030003464 @default.
• W52984345 cites W2034778864 @default.
• W52984345 cites W2035663183 @default.
• W52984345 cites W2038084674 @default.
• W52984345 cites W2038278728 @default.
• W52984345 cites W2052953575 @default.
• W52984345 cites W2077327610 @default.
• W52984345 cites W2088452335 @default.
• W52984345 cites W2088575436 @default.
• W52984345 cites W2090421889 @default.
• W52984345 cites W2091181995 @default.
• W52984345 cites W2098576707 @default.
• W52984345 cites W2116459658 @default.
• W52984345 cites W2126536182 @default.
• W52984345 cites W2152255652 @default.
• W52984345 cites W2166264907 @default.
• W52984345 cites W2320293007 @default.
• W52984345 cites W4234388694 @default.
• W52984345 doi "https://doi.org/10.3904/kjim.2001.16.3.187" @default.
• W52984345 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4531721" @default.
• W52984345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11769578" @default.
• W52984345 hasPublicationYear "2001" @default.
• W52984345 type Work @default.
• W52984345 sameAs 52984345 @default.
• W52984345 citedByCount "13" @default.
• W52984345 countsByYear W529843452018 @default.
• W52984345 countsByYear W529843452020 @default.
• W52984345 countsByYear W529843452022 @default.
• W52984345 countsByYear W529843452023 @default.
• W52984345 crossrefType "journal-article" @default.
• W52984345 hasAuthorship W52984345A5004961134 @default.
• W52984345 hasAuthorship W52984345A5023837417 @default.
• W52984345 hasAuthorship W52984345A5039000978 @default.
• W52984345 hasAuthorship W52984345A5048656815 @default.
• W52984345 hasAuthorship W52984345A5061142393 @default.
• W52984345 hasAuthorship W52984345A5065930316 @default.
• W52984345 hasBestOaLocation W529843451 @default.
• W52984345 hasConcept C126322002 @default.
• W52984345 hasConcept C134018914 @default.
• W52984345 hasConcept C159654299 @default.
• W52984345 hasConcept C163764329 @default.
• W52984345 hasConcept C170493617 @default.
• W52984345 hasConcept C195616568 @default.
• W52984345 hasConcept C203014093 @default.
• W52984345 hasConcept C2776652619 @default.
• W52984345 hasConcept C2777608072 @default.
• W52984345 hasConcept C2779134260 @default.
• W52984345 hasConcept C45121317 @default.
• W52984345 hasConcept C50181227 @default.
• W52984345 hasConcept C63363279 @default.
• W52984345 hasConcept C71924100 @default.
• W52984345 hasConceptScore W52984345C126322002 @default.
• W52984345 hasConceptScore W52984345C134018914 @default.
• W52984345 hasConceptScore W52984345C159654299 @default.
• W52984345 hasConceptScore W52984345C163764329 @default.
• W52984345 hasConceptScore W52984345C170493617 @default.
• W52984345 hasConceptScore W52984345C195616568 @default.
• W52984345 hasConceptScore W52984345C203014093 @default.
• W52984345 hasConceptScore W52984345C2776652619 @default.
• W52984345 hasConceptScore W52984345C2777608072 @default.
• W52984345 hasConceptScore W52984345C2779134260 @default.
• W52984345 hasConceptScore W52984345C45121317 @default.
• W52984345 hasConceptScore W52984345C50181227 @default.
• W52984345 hasConceptScore W52984345C63363279 @default.
• W52984345 hasConceptScore W52984345C71924100 @default.
• W52984345 hasIssue "3" @default.
• W52984345 hasLocation W529843451 @default.
• W52984345 hasLocation W529843452 @default.
• W52984345 hasLocation W529843453 @default.
• W52984345 hasLocation W529843454 @default.
• W52984345 hasOpenAccess W52984345 @default.
• W52984345 hasPrimaryLocation W529843451 @default.

• next